fluticasone propionate + salmeterol xinafoate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
fluticasone propionate + salmeterol xinafoate: clinical details
Prescribing considerations
- Confirm that fixed inhaled corticosteroid and LABA therapy is appropriate and that the selected product is licensed for the patient's condition and age.
- Do not initiate during an acute exacerbation or rapidly deteriorating asthma; ensure access to an appropriate fast-acting reliever.
- Review symptom control, reliever use, adherence and inhaler technique regularly.
- Consider systemic corticosteroid exposure from all routes and whether a steroid treatment or emergency card is appropriate.
- AirFluSal MDI spacer choice affects lung and systemic exposure; maintain the same compatible spacer unless treatment is reassessed.
Contraindications and cautions
- Hypersensitivity to fluticasone propionate, salmeterol xinafoate or a formulation excipient.
- Seretide Accuhaler contains lactose that includes milk proteins.
- Use caution with pulmonary tuberculosis or airway infection, significant cardiovascular disease or arrhythmia, thyrotoxicosis, diabetes, hypokalaemia and susceptibility to systemic corticosteroid effects.
Monitoring
- Asthma or COPD control, exacerbations, reliever use and inhaler technique.
- Growth in children receiving prolonged inhaled corticosteroid treatment.
- Clinical evidence of adrenal suppression or other systemic corticosteroid effects when exposure is high or prolonged.
- Blood glucose or potassium where clinical risk factors or interacting treatments are present.
- Pneumonia features in COPD, recognising overlap with exacerbation symptoms.
- Visual symptoms, with ophthalmic assessment where indicated.
Clinical pharmacology
Salmeterol is a selective long-acting beta2-adrenoceptor agonist that provides sustained bronchodilation. Inhaled fluticasone propionate produces local glucocorticoid anti-inflammatory activity; swallowed fluticasone undergoes extensive first-pass CYP3A4 metabolism, although strong CYP3A4 inhibition can substantially increase systemic exposure.
Formulation and product differences
- AirFluSal MDI is a pressurised suspension requiring coordinated actuation and inhalation; compatible spacers may be used. It is licensed for adults with asthma and not for COPD.
- Seretide Accuhaler is a breath-actuated, pre-dispensed dry-powder device with an indicator. It contains lactose with milk proteins, has broader age-specific asthma licensing and includes a presentation licensed for defined adults with COPD.
- Device technique, inspiratory requirements, excipients and licensing are not interchangeable; prescribe and train for the specific inhaler.
fluticasone propionate + salmeterol xinafoate preparations and strengths
Inhaled preparation
Route: Inhaled
Strengths: 25 micrograms + 125 micrograms/actuation, 25 micrograms + 125 micrograms/metered dose, 25 micrograms + 250 micrograms/actuation, 25 micrograms + 250 micrograms/metered dose, 25 micrograms + 50 micrograms/metered dose, 50 micrograms + 100 micrograms/dose, 50 micrograms + 250 micrograms/dose, 50 micrograms + 500 micrograms/actuation, 50 micrograms + 500 micrograms/dose
fluticasone propionate + salmeterol xinafoate interactions
Tell your prescriber or pharmacist about all inhaled, prescribed and over-the-counter treatments. Important interactions include:
Ritonavir or cobicistat
These can markedly increase systemic fluticasone exposure, causing adrenal suppression or Cushing-like effects. Combined use usually requires avoidance or specialist management.
Ketoconazole, itraconazole and other strong CYP3A4 inhibitors
These can increase exposure to fluticasone and salmeterol, raising the risk of systemic steroid effects, palpitations and QT-interval prolongation.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.